Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
Mené sur 658 patientes atteintes d'un cancer du sein de stade précoce sans envahissement ganglionnaire et à haut risque (âge médian : 53 ans), cet essai de phase III compare l'efficacité, du point de vue de la survie sans maladie, et la toxicité d'une administration séquentielle d'épirubicine et de docétaxel et d'une administration concomitante de ces deux agents, en traitement adjuvant
While the role of adjuvant chemotherapy for patients with early-stage breast cancer has been clearly established (Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005), a number of important clinical questions remain unanswered in certain groups. Although it has been shown that long-term outcomes are improved with anthracycline and taxane-containing regimens relative to anthracyclines alone (Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2012), no single regimen has been consistently found to be superior, resulting in an area of significant clinical equipoise.
British Journal of Cancer , éditorial, 2016